NVP 231

NVP 231 is a potent, specific, and reversible ceramide kinase (CerK) inhibitor (IC50=12 nM) that competitively inhibits binding of ceramide to CerK[1]. NVP 231 induces cell apoptosis by increasing DNA fragmentation and caspase-3 and caspase-9 cleavage[2].

Product Specifications

CAS Number

[362003-83-6]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Apoptosis

Type

Reference compound

Related Pathways

Apoptosis

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/NVP-231.html

Purity

99.73

Solubility

DMSO : ≥ 41 mg/mL

Smiles

O=C(C1(C[C@@H](C2)C3)C[C@@H]3C[C@@H]2C1)NC4=CC=C5N=C(NC(C6=CC=CC=C6)=O)SC5=C4

Molecular Formula

C25H25N3O2S

Molecular Weight

431.55

Precautions

H302, H315, H319, H335

References & Citations

[1]Graf C, et al. Targeting ceramide metabolism with a potent and specific ceramide kinase inhibitor. Mol Pharmacol. 2008 Oct;74 (4) :925-32.|[2]Graf C, et al. A secondary assay for ceramide kinase inhibitors based on cell growth inhibition by short-chain ceramides. Anal Biochem. 2009 Jan 1;384 (1) :166-9.|[3]Pastukhov O, et al. The ceramide kinase inhibitor NVP-231 inhibits breast and lung cancer cell proliferation by inducing M phase arrest and subsequent cell death.Br J Pharmacol. 2014 Dec;171 (24) :5829-44.